Which has better valuation & earnings, CTNM or HCM?

HUTCHMED has higher revenue and earnings than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics $50M 12.93 -$59.98M -$1.73 N/A HUTCHMED $549.12M 4.01 $456.91M N/A N/A

Is CTNM or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% HUTCHMED N/A N/A N/A

Does the media prefer CTNM or HCM?

In the previous week, Contineum Therapeutics had 2 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Contineum Therapeutics and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.93 beat Contineum Therapeutics' score of 0.49 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTNM or GHRS more profitable?

GH Research's return on equity of -20.07% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% GH Research N/A -20.07% -19.41%

Does the media favor CTNM or GHRS?

In the previous week, Contineum Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for GH Research. Contineum Therapeutics' average media sentiment score of 0.49 beat GH Research's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CTNM or CMPS more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Compass Pathways N/A -49.63% -13.08%

Does the media favor CTNM or CMPS?

In the previous week, Contineum Therapeutics had 5 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.66 beat Contineum Therapeutics' score of 0.49 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CTNM or TRLV?

Trulieve Cannabis has lower revenue, but higher earnings than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics $50M 12.93 -$59.98M -$1.73 N/A Trulieve Cannabis N/A N/A N/A N/A N/A

Is CTNM or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Trulieve Cannabis N/A N/A N/A

Does the media prefer CTNM or TRLV?

In the previous week, Contineum Therapeutics had 5 more articles in the media than Trulieve Cannabis. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Trulieve Cannabis. Contineum Therapeutics' average media sentiment score of 0.49 beat Trulieve Cannabis' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRGO or CTNM?

In the previous week, Contineum Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Contineum Therapeutics and 5 mentions for Perrigo. Contineum Therapeutics' average media sentiment score of 0.49 beat Perrigo's score of 0.40 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Contineum Therapeutics (CTNM) Competitors

$17.19 +1.17 (+7.30%)

As of 08/21/2026 04:00 PM Eastern

Compare

CTNM vs. HCM, GHRS, CMPS, TRLV, and PRGO

Should you buy Contineum Therapeutics stock or one of its competitors? Contineum Therapeutics's main competitors and comparable companies include HUTCHMED (HCM), GH Research (GHRS), Compass Pathways (CMPS), Trulieve Cannabis (TRLV), and Perrigo (PRGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Contineum Therapeutics compare to HUTCHMED?

Contineum Therapeutics (NASDAQ:CTNM) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

8.8% of HUTCHMED shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HUTCHMED has higher revenue and earnings than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A
HUTCHMED	$549.12M	4.01	$456.91M	N/A	N/A

HUTCHMED's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
HUTCHMED	N/A	N/A	N/A

In the previous week, Contineum Therapeutics had 2 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Contineum Therapeutics and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.93 beat Contineum Therapeutics' score of 0.49 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 17.80%. HUTCHMED has a consensus price target of $14.87, suggesting a potential upside of 17.71%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

Contineum Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Summary

Contineum Therapeutics and HUTCHMED tied by winning 7 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to GH Research?

Contineum Therapeutics (NASDAQ:CTNM) and GH Research (NASDAQ:GHRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

GH Research has lower revenue, but higher earnings than Contineum Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

Contineum Therapeutics presently has a consensus target price of $20.25, suggesting a potential upside of 17.80%. GH Research has a consensus target price of $45.00, suggesting a potential upside of 58.84%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

56.9% of GH Research shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Contineum Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for GH Research. Contineum Therapeutics' average media sentiment score of 0.49 beat GH Research's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research's return on equity of -20.07% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
GH Research	N/A	-20.07%	-19.41%

Contineum Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, GH Research has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Summary

GH Research beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Compass Pathways?

Contineum Therapeutics (NASDAQ:CTNM) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Compass Pathways	N/A	-49.63%	-13.08%

46.2% of Compass Pathways shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Contineum Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Contineum Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 17.80%. Compass Pathways has a consensus price target of $23.36, suggesting a potential upside of 75.22%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Contineum Therapeutics has higher revenue and earnings than Compass Pathways. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

In the previous week, Contineum Therapeutics had 5 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.66 beat Contineum Therapeutics' score of 0.49 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to Trulieve Cannabis?

Contineum Therapeutics (NASDAQ:CTNM) and Trulieve Cannabis (NYSE:TRLV) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Trulieve Cannabis has lower revenue, but higher earnings than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

In the previous week, Contineum Therapeutics had 5 more articles in the media than Trulieve Cannabis. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Trulieve Cannabis. Contineum Therapeutics' average media sentiment score of 0.49 beat Trulieve Cannabis' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis' return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Trulieve Cannabis	N/A	N/A	N/A

Contineum Therapeutics currently has a consensus target price of $20.25, indicating a potential upside of 17.80%. Trulieve Cannabis has a consensus target price of $15.00, indicating a potential upside of 36.12%. Given Trulieve Cannabis' higher probable upside, analysts clearly believe Trulieve Cannabis is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Contineum Therapeutics beats Trulieve Cannabis on 5 of the 8 factors compared between the two stocks.

How does Contineum Therapeutics compare to Perrigo?

Perrigo (NYSE:PRGO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Contineum Therapeutics has lower revenue, but higher earnings than Perrigo. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A

In the previous week, Contineum Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Contineum Therapeutics and 5 mentions for Perrigo. Contineum Therapeutics' average media sentiment score of 0.49 beat Perrigo's score of 0.40 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 35.96%. Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 17.80%. Given Perrigo's higher possible upside, equities analysts clearly believe Perrigo is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Contineum Therapeutics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Contineum Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$646.70M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-9.94	789.80	272.88	24.24
Price / Sales	12.93	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	2.70	11.89	13.05	6.20
Net Income	-$59.98M	$2.81B	$3.47B	$348.59M
7 Day Performance	21.14%	1.77%	2.09%	0.08%
1 Month Performance	19.62%	3.85%	6.64%	3.88%
1 Year Performance	72.94%	6.56%	25.02%	16.98%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	1.144 of 5 stars	$17.19 +7.3%	$20.25 +17.8%	+72.9%	$646.70M	$50M	N/A	31	News Coverage Analyst Upgrade
HCM HUTCHMED	2.4488 of 5 stars	$12.49 -1.2%	$14.87 +19.1%	-21.6%	$2.18B	$548.51M	N/A	1,796	Gap Up
GHRS GH Research	2.1384 of 5 stars	$29.91 +0.6%	$45.00 +50.5%	+116.6%	$2.05B	N/A	N/A	10	Positive News
CMPS Compass Pathways	2.4623 of 5 stars	$13.81 -0.6%	$23.36 +69.1%	+189.2%	$1.92B	N/A	N/A	120
TRLV Trulieve Cannabis	3.6438 of 5 stars	$9.86 +1.8%	$15.00 +52.1%	N/A	$1.90B	N/A	N/A	5,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. HCM, GHRS, CMPS, TRLV, and PRGO

How does Contineum Therapeutics compare to HUTCHMED?

Summary

How does Contineum Therapeutics compare to GH Research?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Summary

How does Contineum Therapeutics compare to Trulieve Cannabis?

Summary

How does Contineum Therapeutics compare to Perrigo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. HCM, GHRS, CMPS, TRLV, and PRGO

How does Contineum Therapeutics compare to HUTCHMED?

Do insiders and institutionals have more ownership in CTNM or HCM?

Which has better valuation & earnings, CTNM or HCM?

Is CTNM or HCM more profitable?

Does the media prefer CTNM or HCM?

Do analysts prefer CTNM or HCM?

Which has more volatility and risk, CTNM or HCM?

Summary

How does Contineum Therapeutics compare to GH Research?

Which has stronger earnings & valuation, CTNM or GHRS?

Do analysts rate CTNM or GHRS?

Do insiders and institutionals have more ownership in CTNM or GHRS?

Does the media favor CTNM or GHRS?

Is CTNM or GHRS more profitable?

Which has more volatility and risk, CTNM or GHRS?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Is CTNM or CMPS more profitable?

Do institutionals & insiders have more ownership in CTNM or CMPS?

Which has more volatility & risk, CTNM or CMPS?

Do analysts prefer CTNM or CMPS?

Which has higher valuation & earnings, CTNM or CMPS?

Does the media favor CTNM or CMPS?

Summary

How does Contineum Therapeutics compare to Trulieve Cannabis?

Which has preferable earnings & valuation, CTNM or TRLV?

Does the media prefer CTNM or TRLV?

Is CTNM or TRLV more profitable?

Do analysts rate CTNM or TRLV?

Summary

How does Contineum Therapeutics compare to Perrigo?

Which has better earnings & valuation, PRGO or CTNM?

Does the media favor PRGO or CTNM?

Do analysts prefer PRGO or CTNM?

Is PRGO or CTNM more profitable?

Which has more risk & volatility, PRGO or CTNM?

Do insiders and institutionals have more ownership in PRGO or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools